{"id":53609,"date":"2023-02-03T12:02:47","date_gmt":"2023-02-03T11:02:47","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/global-pulmonary-arterial-hypertension-pah-drugs-market-report-2022-to-2027-key-players-include-arena-pharmaceuticals-astrazeneca-bayer-aktiengesellschaft-and-daiichi-sankyo-researchandmarkets\/"},"modified":"2023-02-03T12:02:47","modified_gmt":"2023-02-03T11:02:47","slug":"global-pulmonary-arterial-hypertension-pah-drugs-market-report-2022-to-2027-key-players-include-arena-pharmaceuticals-astrazeneca-bayer-aktiengesellschaft-and-daiichi-sankyo-researchandmarkets","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/global-pulmonary-arterial-hypertension-pah-drugs-market-report-2022-to-2027-key-players-include-arena-pharmaceuticals-astrazeneca-bayer-aktiengesellschaft-and-daiichi-sankyo-researchandmarkets\/","title":{"rendered":"Global Pulmonary Arterial Hypertension (PAH) Drugs Market Report 2022 to 2027: Key Players Include Arena Pharmaceuticals, AstraZeneca, Bayer Aktiengesellschaft and Daiichi Sankyo &#8211; ResearchAndMarkets.com"},"content":{"rendered":"<div>\n<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/5656465\/pulmonary-arterial-hypertension-pah-drugs?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=754r8l&amp;utm_campaign=1816813+-+Global+Pulmonary+Arterial+Hypertension+(PAH)+Drugs+Market+Report+2022+to+2027%3A+Key+Players+Include+Arena+Pharmaceuticals%2C+AstraZeneca%2C+Bayer+Aktiengesellschaft+and+Daiichi+Sankyo&amp;utm_exec=jamu273prd\" rel=\"nofollow noopener\" shape=\"rect\">&#8220;Pulmonary Arterial Hypertension (PAH) Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027&#8221;<\/a> report has been added to <strong>ResearchAndMarkets.com&#8217;s<\/strong> offering.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20230203005204\/en\/1704781\/4\/logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230203005204\/en\/1704781\/21\/logo.jpg\"><\/a><\/p>\n<p>\nThe global pulmonary arterial hypertension (PAH) drugs market size reached US$ 6.9 Billion in 2021. Looking forward, the publisher expects the market to reach US$ 9.4 Billion by 2027, exhibiting a CAGR of 5.29% during 2021-2027.\n<\/p>\n<p>\n<strong>Companies Mentioned<\/strong>\n<\/p>\n<ul>\n<li>\nActelion Pharmaceuticals Ltd (Johnson &amp; Johnson)\n<\/li>\n<li>\nArena Pharmaceuticals Inc.\n<\/li>\n<li>\nAstraZeneca PLC\n<\/li>\n<li>\nBayer Aktiengesellschaft\n<\/li>\n<li>\nDaiichi Sankyo Company Limited\n<\/li>\n<li>\nGilead Science Inc.\n<\/li>\n<li>\nGlaxoSmithKline PLC\n<\/li>\n<li>\nMerck KGaA\n<\/li>\n<li>\nNovartis International AG\n<\/li>\n<li>\nPfizer Inc.\n<\/li>\n<li>\nUnited Therapeutics Corporation\n<\/li>\n<\/ul>\n<p>\nKeeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.\n<\/p>\n<p>\nPulmonary arterial hypertension (PAH) refers to a life-threatening medical condition characterized by high blood pressure in the arteries that connect the heart to the lungs. It causes the artery walls to tighten and narrow down, thereby exerting additional pressure on the heart to pump blood and weakening the muscles.\n<\/p>\n<p>\nIn adverse cases, it can also compromise the heart&#8217;s capacity to pump blood, thus eventually causing heart failure. PAH is characterized by shortness of breath, fatigue and swelling in ankles and legs. It is diagnosed through various tests, such as an echocardiogram, computer tomography (CT) scans, chest X-rays and ventilation-perfusion scans.\n<\/p>\n<p>\nIt is usually treated using various drugs, such as endothelin receptor antagonists (ERAs), vasodilators, calcium channel blockers (CCBs), anticoagulants, diuretics and cardiac glycosides. These drugs can be inhaled, injected or orally administered.\n<\/p>\n<p>\nThe increasing prevalence of cardiovascular and pulmonary disorders is one of the key factors driving the growth of the market. Furthermore, the rising geriatric population that is more susceptible to such medical ailments is providing a boost to the market growth.\n<\/p>\n<p>\nIn line with this, changes in lifestyles, such as excessive alcohol consumption, a lack of physical activity, and unhealthy dietary patterns, have enhanced the risks of hypertension and high blood pressure.\n<\/p>\n<p>\nThis, along with the development of novel orphan drugs and technologically advanced devices for the treatment of PAH, is favoring the market growth. Other factors, including increasing awareness among the masses regarding the available treatment alternatives for PAH, and improving healthcare infrastructure across the globe, are expected to drive the market further.\n<\/p>\n<p>\n<strong>Key Market Segmentation:<\/strong>\n<\/p>\n<p>\nThe publisher provides an analysis of the key trends in each sub-segment of the global pulmonary arterial hypertension (PAH) drugs market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on drug class, route of administration and end user.\n<\/p>\n<p>\n<strong>Breakup by Drug Class:<\/strong>\n<\/p>\n<ul>\n<li>\nEndothelin Receptor Antagonists (ERAs)\n<\/li>\n<li>\nVasodilators\n<\/li>\n<li>\nPhosphodiesterase-5 (PDE-5) Inhibitors\n<\/li>\n<li>\nSoluble Guanylate Cyclase (sGC) Stimulators\n<\/li>\n<li>\nCalcium Channel Blockers (CCBs)\n<\/li>\n<li>\nProstacyclin and Prostacyclin Analogs\n<\/li>\n<li>\nOthers\n<\/li>\n<\/ul>\n<p>\n<strong>Breakup by Route of Administration:<\/strong>\n<\/p>\n<ul>\n<li>\nInhalation\n<\/li>\n<li>\nInjectable\n<\/li>\n<li>\nOral Administration\n<\/li>\n<\/ul>\n<p>\n<strong>Breakup by End User:<\/strong>\n<\/p>\n<ul>\n<li>\nHospitals\n<\/li>\n<li>\nClinics\n<\/li>\n<li>\nOthers\n<\/li>\n<\/ul>\n<p>\n<strong>Breakup by Region:<\/strong>\n<\/p>\n<ul>\n<li>\nNorth America\n<\/li>\n<li>\nUnited States\n<\/li>\n<li>\nCanada\n<\/li>\n<li>\nAsia Pacific\n<\/li>\n<li>\nChina\n<\/li>\n<li>\nJapan\n<\/li>\n<li>\nIndia\n<\/li>\n<li>\nSouth Korea\n<\/li>\n<li>\nAustralia\n<\/li>\n<li>\nIndonesia\n<\/li>\n<li>\nOthers\n<\/li>\n<li>\nEurope\n<\/li>\n<li>\nGermany\n<\/li>\n<li>\nFrance\n<\/li>\n<li>\nUnited Kingdom\n<\/li>\n<li>\nItaly\n<\/li>\n<li>\nSpain\n<\/li>\n<li>\nRussia\n<\/li>\n<li>\nOthers\n<\/li>\n<li>\nLatin America\n<\/li>\n<li>\nBrazil\n<\/li>\n<li>\nMexico\n<\/li>\n<li>\nOthers\n<\/li>\n<li>\nMiddle East and Africa\n<\/li>\n<\/ul>\n<p>\n<strong>Key Questions Answered in This Report:<\/strong>\n<\/p>\n<ul>\n<li>\nHow has the global pulmonary arterial hypertension (PAH) drugs market performed so far and how will it perform in the coming years?\n<\/li>\n<li>\nWhat has been the impact of COVID-19 on the global pulmonary arterial hypertension (PAH) drugs market?\n<\/li>\n<li>\nWhat are the key regional markets?\n<\/li>\n<li>\nWhat is the breakup of the market based on the drug class?\n<\/li>\n<li>\nWhat is the breakup of the market based on the route of administration?\n<\/li>\n<li>\nWhat is the breakup of the market based on the end user?\n<\/li>\n<li>\nWhat are the various stages in the value chain of the industry?\n<\/li>\n<li>\nWhat are the key driving factors and challenges in the industry?\n<\/li>\n<li>\nWhat is the structure of the global pulmonary arterial hypertension (PAH) drugs market and who are the key players?\n<\/li>\n<li>\nWhat is the degree of competition in the industry?\n<\/li>\n<\/ul>\n<p>\nFor more information about this report visit <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/5656465\/pulmonary-arterial-hypertension-pah-drugs?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=754r8l&amp;utm_campaign=1816813+-+Global+Pulmonary+Arterial+Hypertension+(PAH)+Drugs+Market+Report+2022+to+2027%3A+Key+Players+Include+Arena+Pharmaceuticals%2C+AstraZeneca%2C+Bayer+Aktiengesellschaft+and+Daiichi+Sankyo&amp;utm_exec=jamu273prd\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/www.researchandmarkets.com\/r\/hbqkvm<\/a>\n<\/p>\n<p>\n<strong>About ResearchAndMarkets.com<\/strong>\n<\/p>\n<p>\nResearchAndMarkets.com is the world&#8217;s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nResearchAndMarkets.com<br \/>\n<br \/>Laura Wood, Senior Press Manager<br \/>\n<br \/><a target=\"_blank\" href=\"m&#97;&#x69;&#x6c;t&#111;&#58;&#x70;&#x72;e&#115;&#x73;&#x40;r&#101;&#115;&#x65;&#x61;r&#99;&#x68;&#x61;n&#100;&#109;&#x61;&#x72;k&#101;&#x74;&#x73;&#46;&#99;&#111;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#x70;&#x72;&#x65;&#115;&#115;&#64;r&#x65;&#x73;&#x65;&#x61;&#114;&#99;ha&#x6e;&#x64;&#x6d;&#97;&#114;&#107;et&#x73;&#x2e;&#x63;&#111;&#109;<\/a><br \/>For E.S.T Office Hours Call 1-917-300-0470<br \/>\n<br \/>For U.S.\/ CAN Toll Free Call 1-800-526-8630<br \/>\n<br \/>For GMT Office Hours Call +353-1-416-8900\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Pulmonary Arterial Hypertension (PAH) Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. The global pulmonary arterial hypertension (PAH) drugs market size reached US$ 6.9 Billion in 2021. Looking forward, the publisher expects the market to reach US$ 9.4 Billion by 2027, exhibiting &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/global-pulmonary-arterial-hypertension-pah-drugs-market-report-2022-to-2027-key-players-include-arena-pharmaceuticals-astrazeneca-bayer-aktiengesellschaft-and-daiichi-sankyo-researchandmarkets\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":["entry","post","publish","author-business","post-53609","format-standard","category-industry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Global Pulmonary Arterial Hypertension (PAH) Drugs Market Report 2022 to 2027: Key Players Include Arena Pharmaceuticals, AstraZeneca, Bayer Aktiengesellschaft and Daiichi Sankyo - ResearchAndMarkets.com - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/global-pulmonary-arterial-hypertension-pah-drugs-market-report-2022-to-2027-key-players-include-arena-pharmaceuticals-astrazeneca-bayer-aktiengesellschaft-and-daiichi-sankyo-researchandmarkets\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Global Pulmonary Arterial Hypertension (PAH) Drugs Market Report 2022 to 2027: Key Players Include Arena Pharmaceuticals, AstraZeneca, Bayer Aktiengesellschaft and Daiichi Sankyo - ResearchAndMarkets.com - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Pulmonary Arterial Hypertension (PAH) Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. The global pulmonary arterial hypertension (PAH) drugs market size reached US$ 6.9 Billion in 2021. Looking forward, the publisher expects the market to reach US$ 9.4 Billion by 2027, exhibiting ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/global-pulmonary-arterial-hypertension-pah-drugs-market-report-2022-to-2027-key-players-include-arena-pharmaceuticals-astrazeneca-bayer-aktiengesellschaft-and-daiichi-sankyo-researchandmarkets\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-03T11:02:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230203005204\/en\/1704781\/21\/logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-pulmonary-arterial-hypertension-pah-drugs-market-report-2022-to-2027-key-players-include-arena-pharmaceuticals-astrazeneca-bayer-aktiengesellschaft-and-daiichi-sankyo-researchandmarkets\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-pulmonary-arterial-hypertension-pah-drugs-market-report-2022-to-2027-key-players-include-arena-pharmaceuticals-astrazeneca-bayer-aktiengesellschaft-and-daiichi-sankyo-researchandmarkets\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Global Pulmonary Arterial Hypertension (PAH) Drugs Market Report 2022 to 2027: Key Players Include Arena Pharmaceuticals, AstraZeneca, Bayer Aktiengesellschaft and Daiichi Sankyo &#8211; ResearchAndMarkets.com\",\"datePublished\":\"2023-02-03T11:02:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-pulmonary-arterial-hypertension-pah-drugs-market-report-2022-to-2027-key-players-include-arena-pharmaceuticals-astrazeneca-bayer-aktiengesellschaft-and-daiichi-sankyo-researchandmarkets\\\/\"},\"wordCount\":778,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-pulmonary-arterial-hypertension-pah-drugs-market-report-2022-to-2027-key-players-include-arena-pharmaceuticals-astrazeneca-bayer-aktiengesellschaft-and-daiichi-sankyo-researchandmarkets\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230203005204\\\/en\\\/1704781\\\/21\\\/logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-pulmonary-arterial-hypertension-pah-drugs-market-report-2022-to-2027-key-players-include-arena-pharmaceuticals-astrazeneca-bayer-aktiengesellschaft-and-daiichi-sankyo-researchandmarkets\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-pulmonary-arterial-hypertension-pah-drugs-market-report-2022-to-2027-key-players-include-arena-pharmaceuticals-astrazeneca-bayer-aktiengesellschaft-and-daiichi-sankyo-researchandmarkets\\\/\",\"name\":\"Global Pulmonary Arterial Hypertension (PAH) Drugs Market Report 2022 to 2027: Key Players Include Arena Pharmaceuticals, AstraZeneca, Bayer Aktiengesellschaft and Daiichi Sankyo - ResearchAndMarkets.com - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-pulmonary-arterial-hypertension-pah-drugs-market-report-2022-to-2027-key-players-include-arena-pharmaceuticals-astrazeneca-bayer-aktiengesellschaft-and-daiichi-sankyo-researchandmarkets\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-pulmonary-arterial-hypertension-pah-drugs-market-report-2022-to-2027-key-players-include-arena-pharmaceuticals-astrazeneca-bayer-aktiengesellschaft-and-daiichi-sankyo-researchandmarkets\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230203005204\\\/en\\\/1704781\\\/21\\\/logo.jpg\",\"datePublished\":\"2023-02-03T11:02:47+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-pulmonary-arterial-hypertension-pah-drugs-market-report-2022-to-2027-key-players-include-arena-pharmaceuticals-astrazeneca-bayer-aktiengesellschaft-and-daiichi-sankyo-researchandmarkets\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-pulmonary-arterial-hypertension-pah-drugs-market-report-2022-to-2027-key-players-include-arena-pharmaceuticals-astrazeneca-bayer-aktiengesellschaft-and-daiichi-sankyo-researchandmarkets\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-pulmonary-arterial-hypertension-pah-drugs-market-report-2022-to-2027-key-players-include-arena-pharmaceuticals-astrazeneca-bayer-aktiengesellschaft-and-daiichi-sankyo-researchandmarkets\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230203005204\\\/en\\\/1704781\\\/21\\\/logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230203005204\\\/en\\\/1704781\\\/21\\\/logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-pulmonary-arterial-hypertension-pah-drugs-market-report-2022-to-2027-key-players-include-arena-pharmaceuticals-astrazeneca-bayer-aktiengesellschaft-and-daiichi-sankyo-researchandmarkets\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Global Pulmonary Arterial Hypertension (PAH) Drugs Market Report 2022 to 2027: Key Players Include Arena Pharmaceuticals, AstraZeneca, Bayer Aktiengesellschaft and Daiichi Sankyo &#8211; ResearchAndMarkets.com\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Global Pulmonary Arterial Hypertension (PAH) Drugs Market Report 2022 to 2027: Key Players Include Arena Pharmaceuticals, AstraZeneca, Bayer Aktiengesellschaft and Daiichi Sankyo - ResearchAndMarkets.com - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/global-pulmonary-arterial-hypertension-pah-drugs-market-report-2022-to-2027-key-players-include-arena-pharmaceuticals-astrazeneca-bayer-aktiengesellschaft-and-daiichi-sankyo-researchandmarkets\/","og_locale":"en_US","og_type":"article","og_title":"Global Pulmonary Arterial Hypertension (PAH) Drugs Market Report 2022 to 2027: Key Players Include Arena Pharmaceuticals, AstraZeneca, Bayer Aktiengesellschaft and Daiichi Sankyo - ResearchAndMarkets.com - Pharma Trend","og_description":"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Pulmonary Arterial Hypertension (PAH) Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. The global pulmonary arterial hypertension (PAH) drugs market size reached US$ 6.9 Billion in 2021. Looking forward, the publisher expects the market to reach US$ 9.4 Billion by 2027, exhibiting ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/global-pulmonary-arterial-hypertension-pah-drugs-market-report-2022-to-2027-key-players-include-arena-pharmaceuticals-astrazeneca-bayer-aktiengesellschaft-and-daiichi-sankyo-researchandmarkets\/","og_site_name":"Pharma Trend","article_published_time":"2023-02-03T11:02:47+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230203005204\/en\/1704781\/21\/logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/global-pulmonary-arterial-hypertension-pah-drugs-market-report-2022-to-2027-key-players-include-arena-pharmaceuticals-astrazeneca-bayer-aktiengesellschaft-and-daiichi-sankyo-researchandmarkets\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/global-pulmonary-arterial-hypertension-pah-drugs-market-report-2022-to-2027-key-players-include-arena-pharmaceuticals-astrazeneca-bayer-aktiengesellschaft-and-daiichi-sankyo-researchandmarkets\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Global Pulmonary Arterial Hypertension (PAH) Drugs Market Report 2022 to 2027: Key Players Include Arena Pharmaceuticals, AstraZeneca, Bayer Aktiengesellschaft and Daiichi Sankyo &#8211; ResearchAndMarkets.com","datePublished":"2023-02-03T11:02:47+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/global-pulmonary-arterial-hypertension-pah-drugs-market-report-2022-to-2027-key-players-include-arena-pharmaceuticals-astrazeneca-bayer-aktiengesellschaft-and-daiichi-sankyo-researchandmarkets\/"},"wordCount":778,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/global-pulmonary-arterial-hypertension-pah-drugs-market-report-2022-to-2027-key-players-include-arena-pharmaceuticals-astrazeneca-bayer-aktiengesellschaft-and-daiichi-sankyo-researchandmarkets\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230203005204\/en\/1704781\/21\/logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/global-pulmonary-arterial-hypertension-pah-drugs-market-report-2022-to-2027-key-players-include-arena-pharmaceuticals-astrazeneca-bayer-aktiengesellschaft-and-daiichi-sankyo-researchandmarkets\/","url":"https:\/\/pharma-trend.com\/en\/global-pulmonary-arterial-hypertension-pah-drugs-market-report-2022-to-2027-key-players-include-arena-pharmaceuticals-astrazeneca-bayer-aktiengesellschaft-and-daiichi-sankyo-researchandmarkets\/","name":"Global Pulmonary Arterial Hypertension (PAH) Drugs Market Report 2022 to 2027: Key Players Include Arena Pharmaceuticals, AstraZeneca, Bayer Aktiengesellschaft and Daiichi Sankyo - ResearchAndMarkets.com - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/global-pulmonary-arterial-hypertension-pah-drugs-market-report-2022-to-2027-key-players-include-arena-pharmaceuticals-astrazeneca-bayer-aktiengesellschaft-and-daiichi-sankyo-researchandmarkets\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/global-pulmonary-arterial-hypertension-pah-drugs-market-report-2022-to-2027-key-players-include-arena-pharmaceuticals-astrazeneca-bayer-aktiengesellschaft-and-daiichi-sankyo-researchandmarkets\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230203005204\/en\/1704781\/21\/logo.jpg","datePublished":"2023-02-03T11:02:47+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/global-pulmonary-arterial-hypertension-pah-drugs-market-report-2022-to-2027-key-players-include-arena-pharmaceuticals-astrazeneca-bayer-aktiengesellschaft-and-daiichi-sankyo-researchandmarkets\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/global-pulmonary-arterial-hypertension-pah-drugs-market-report-2022-to-2027-key-players-include-arena-pharmaceuticals-astrazeneca-bayer-aktiengesellschaft-and-daiichi-sankyo-researchandmarkets\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/global-pulmonary-arterial-hypertension-pah-drugs-market-report-2022-to-2027-key-players-include-arena-pharmaceuticals-astrazeneca-bayer-aktiengesellschaft-and-daiichi-sankyo-researchandmarkets\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230203005204\/en\/1704781\/21\/logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230203005204\/en\/1704781\/21\/logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/global-pulmonary-arterial-hypertension-pah-drugs-market-report-2022-to-2027-key-players-include-arena-pharmaceuticals-astrazeneca-bayer-aktiengesellschaft-and-daiichi-sankyo-researchandmarkets\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Global Pulmonary Arterial Hypertension (PAH) Drugs Market Report 2022 to 2027: Key Players Include Arena Pharmaceuticals, AstraZeneca, Bayer Aktiengesellschaft and Daiichi Sankyo &#8211; ResearchAndMarkets.com"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53609","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=53609"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53609\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=53609"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=53609"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=53609"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}